NeuroMetrix, Inc. (NURO)
Stock Price Chart
Key Info
| Market Cap | 7.83M |
| Revenue (ttm) | 7.28M |
| Net Income (ttm) | -2.82M |
| Shares Out | 3.78M |
| EPS (ttm) | -1.19 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | November 30 |
| Last Price | $2.07 |
| Previous Close | $2.04 |
| Change ($) | 0.03 |
| Change (%) | 1.47% |
| Day's Open | 2.06 |
| Day's Range | 2.03 - 2.09 |
| Day's Volume | 159,267 |
| 52-Week Range | 0.86 - 5.19 |
More Stats
| Market Cap | 7.83M |
| Enterprise Value | 4.08M |
| Earnings Date (est) | n/a |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 3.78M |
| Float | n/a |
| EPS (basic) | -1.60 |
| EPS (diluted) | -1.19 |
| FCF / Share | -0.64 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 165,171 |
| Short Ratio | 1.73 |
| Short % of Float | n/a |
| Beta | 2.87 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 1.08 |
| PB Ratio | 1.44 |
| Revenue | 7.28M |
| Operating Income | -3.43M |
| Net Income | -2.82M |
| Free Cash Flow | -2.41M |
| Net Cash | 3.75M |
| Net Cash / Share | 0.99 |
| Gross Margin | 56.93% |
| Operating Margin | -47.12% |
| Profit Margin | -38.80% |
| FCF Margin | -33.07% |
| ROA | -23.17% |
| ROE | -63.12% |
| ROIC | -141.50% |
Analyst Forecasts
Analyst Consensus: n/a
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.27 | 16.09 | 17.09 | 12.03 | 7.30 | 5.51 | 5.28 | 7.58 | 10.40 | 13.90 |
| Revenue Growth | -42.37% | -5.86% | 42.11% | 64.76% | 32.42% | 4.43% | -30.32% | -27.14% | -25.2% | - |
| Gross Profit | 2.25 | 7.38 | 6.86 | 4.91 | 3.35 | 2.94 | 3.08 | 3.99 | 5.67 | 6.85 |
| Operating Income | -11.53 | -12.29 | -13.08 | -15.21 | -13.28 | -8.77 | -7.36 | -10.02 | -10.00 | -17.31 |
| Net Income | -3.77 | 0.02 | -12.86 | -14.91 | -9.19 | -7.77 | -8.02 | -10.01 | -9.98 | -16.89 |
| Shares Outstanding | 0.98 | 0.74 | 0.17 | 0.06 | 0.03 | 0.02 | 0.01 | 0.01 | - | - |
| Earnings Per Share | -3.90 | 0.02 | -115.98 | -582.10 | -620.00 | -492.00 | -982.40 | -1,670.40 | -4,969.60 | -8,451.20 |
| Operating Cash Flow | -3.62 | 2.86 | -12.65 | -15.08 | -13.10 | -7.68 | -6.55 | -9.18 | -6.78 | -13.31 |
| Capital Expenditures | -0.05 | -0.14 | -0.16 | -0.10 | -0.59 | -0.23 | -0.09 | -0.11 | -0.11 | -0.31 |
| Free Cash Flow | -3.67 | 2.72 | -12.82 | -15.18 | -13.69 | -7.91 | -6.64 | -9.28 | -6.89 | -13.61 |
| Cash & Equivalents | 3.13 | 6.78 | 4.04 | 3.95 | 12.46 | 9.22 | 9.20 | 8.70 | 10.52 | 17.39 |
| Total Debt | 1.51 | 1.88 | - | - | - | - | - | 0.02 | 0.04 | 0.06 |
| Net Cash / Debt | 1.62 | 4.90 | 4.04 | 3.95 | 12.46 | 9.22 | 9.20 | 8.68 | 10.48 | 17.34 |
| Assets | 6.89 | 13.99 | 9.60 | 8.28 | 16.10 | 11.40 | 10.80 | 10.88 | 14.22 | 23.07 |
| Liabilities | 4.36 | 7.89 | 4.58 | 3.32 | 3.54 | 8.02 | 3.60 | 2.08 | 3.13 | 2.87 |
| Book Value | 2.53 | 6.10 | 5.02 | 4.96 | 12.56 | 3.39 | 7.19 | 8.80 | 11.09 | 20.20 |
Company Profile
Company Details
| Full Name | NeuroMetrix, Inc. |
| Country | United States |
| Employees | 23 |
| CEO | Shai N. Gozani |
Stock Information
| Ticker Symbol | NURO |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Unique Identifier | NASDAQ: NURO |
Description
NeuroMetrix, a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. Its marketed products include Quell, a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems; DPNCheck, a test used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy; ADVANCE system, a platform for the performance of traditional nerve conduction studies; and SENSUS, a pain therapy device based on transcutaneous electrical nerve stimulation for relief of chronic intractable pain. The company offers its products to consumers, retail merchandisers, direct response TV promoters, health care professionals, managed care organizations, endocrinologists, podiatrists, physicians, neurologists, and physical medicine and rehabilitation centers, as well as primary care, internal medicine, orthopedic, hand, and neurosurgeons. It operates in the United States, Europe, Japan, China, the Middle East, and Mexico. The company has a strategic collaboration with GlaxoSmithKline. NeuroMetrix, Inc. was founded in 1996 and is based in Woburn, Massachusetts.